Small intestinal glucose exposure determines the magnitude of the incretin effect in health and type 2 diabetes

Diabetes

Volumn 63, Issue 8, 2014, Pages 2668-2675

  Marathe, Chinmay S ^b   Rayner, Christopher K ^b   Bound, Michelle ^b   Checklin, Helen ^b   Standfield, Scott ^b   Wishart, Judith ^b   Lange, Kylie ^b   Jones, Karen L ^b   Horowitz, Michael ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Centre of Research Excellence in Translating Nutritional Science to Good Health University of Adelaide ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GENE EXPRESSION REGULATION; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INCRETINS; INSULIN; MALE;

EID: 84905028666     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1757     Document Type: Article

References (23)

1. McIntyre N, Holdsworth CD, Turner DS New interpretation of oral glucose tolerance. Lancet 1964; 2:20-21
2. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24:1076-1082
3. Perley MJ, Kipnis DM Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest 1967; 46:1954-1962
4. Salehi M, Aulinger B, D'Alessio DA. Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. Diabetes 2012; 61: 2728-2733
5. Nauck M, Stöckmann F, Ebert R., Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29:46-52
6. Collins PJ, Horowitz M, Cook D.J., Harding PE, Shearman DJ. Gastric emptying in normal subjects - a reproducible technique using a single scintillation camera and computer system. Gut 1983; 24:1117-1125
7. Marathe CS, Rayner CK, Jones K.L., Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care 2013; 36:1396-1405
8. Pilichiewicz AN, Chaikomin R, Brennan I.M., et al. Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am J Physiol Endocrinol Metab 2007; 293:E743-E753
9. Ma J, Pilichiewicz AN, Feinle-Bisset C, et al. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes. Diabet Med 2012; 29:604-608
10. Holst JJ, Knop FK, Vilsbøll T, Krarup T., Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011; 34(Suppl. 2):S251-S257
11. Bagger JI, Knop FK, Lund A, Vestergaard H., Holst JJ, Vilsbøll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96:737-745
12. Heddle R, Fone D, Dent J., Horowitz M. Stimulation of pyloric motility by intraduodenal dextrose in normal subjects. Gut 1988; 29:1349-1357
13. Trahair LG, Horowitz M, Rayner C.K., et al. Comparative effects of variations in duodenal glucose load on glycemic, insulinemic, and incretin responses in healthy young and older subjects. J Clin Endocrinol Metab 2012; 97: 844-851
14. Højberg PV, Vilsbøll T, Rabøl R, et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009; 52:199-207
15. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124(Suppl.):S3-S18
16. Vilsbøll T., Krarup T, Madsbad S., Holst JJ. Both GLP-1 and GIP are in-sulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003; 114:115-121
17. Schirra J, Katschinski M, Weidmann C., et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996; 97: 92-103
18. Chaikomin R, Doran S, Jones K.L., et al. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. Am J Physiol Endocrinol Metab 2005; 289: E504-E507
19. Näslund E., Grybäck P, Hellström PM, et al. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 1997; 21:387-392
20. Horowitz M, Cook DJ, Collins P.J., et al. Measurement of gastric emptying after gastric bypass surgery using radionuclides. Br J Surg 1982; 69: 655-657
21. Lund A, Vilsbøll T, Bagger J.I., Holst JJ, Knop FK. The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 2011; 300:E1038-E1046
22. Knop FK. Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling? Dia-betologia 2009; 52:2270-2276
23. Lindgren O, Carr RD, Deacon C.F., et al. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin En-docrinol Metab 2011; 96:2519-2524